CL2008001074A1 - Uso de compuestos de triazol, antagonistas de smo para tratar cancer. - Google Patents

Uso de compuestos de triazol, antagonistas de smo para tratar cancer.

Info

Publication number
CL2008001074A1
CL2008001074A1 CL2008001074A CL2008001074A CL2008001074A1 CL 2008001074 A1 CL2008001074 A1 CL 2008001074A1 CL 2008001074 A CL2008001074 A CL 2008001074A CL 2008001074 A CL2008001074 A CL 2008001074A CL 2008001074 A1 CL2008001074 A1 CL 2008001074A1
Authority
CL
Chile
Prior art keywords
treat cancer
triazole compounds
smo antagonists
smo
antagonists
Prior art date
Application number
CL2008001074A
Other languages
English (en)
Spanish (es)
Inventor
James M Balkovec
Sherman T Waddell
Rolf Thieringer
Original Assignee
Merck & Co Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Merck & Co Inc filed Critical Merck & Co Inc
Publication of CL2008001074A1 publication Critical patent/CL2008001074A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4196—1,2,4-Triazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4245—Oxadiazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
CL2008001074A 2007-04-18 2008-04-15 Uso de compuestos de triazol, antagonistas de smo para tratar cancer. CL2008001074A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US92501807P 2007-04-18 2007-04-18

Publications (1)

Publication Number Publication Date
CL2008001074A1 true CL2008001074A1 (es) 2009-06-05

Family

ID=39433852

Family Applications (1)

Application Number Title Priority Date Filing Date
CL2008001074A CL2008001074A1 (es) 2007-04-18 2008-04-15 Uso de compuestos de triazol, antagonistas de smo para tratar cancer.

Country Status (12)

Country Link
US (1) US7691887B2 (enExample)
EP (1) EP2136803B1 (enExample)
JP (1) JP5498936B2 (enExample)
CN (1) CN101663033B (enExample)
AR (1) AR066063A1 (enExample)
AT (1) ATE555785T1 (enExample)
AU (1) AU2008241527B2 (enExample)
CA (1) CA2683946C (enExample)
CL (1) CL2008001074A1 (enExample)
PE (1) PE20090806A1 (enExample)
TW (1) TW200901987A (enExample)
WO (1) WO2008130552A1 (enExample)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI433674B (zh) 2006-12-28 2014-04-11 Infinity Discovery Inc 環杷明(cyclopamine)類似物類
WO2009086451A1 (en) 2007-12-27 2009-07-09 Infinity Pharmaceuticals, Inc. Methods for stereoselective reduction
US20100297118A1 (en) * 2007-12-27 2010-11-25 Macdougall John Therapeutic Cancer Treatments
JP2011522773A (ja) * 2007-12-27 2011-08-04 インフィニティ ファーマスーティカルズ、インク. 治療剤での癌の処置方法
GB0813740D0 (en) * 2008-07-28 2008-09-03 Angeletti P Ist Richerche Biologica Therapeutic compounds
JP5816087B2 (ja) * 2008-08-29 2015-11-18 エンメエッセディ・イタリア・エッセ・エッレ・エッレ Smoアンタゴニストとしての飽和二環式複素環誘導体
CA2769795C (en) 2009-08-05 2020-01-07 Infinity Pharmaceuticals, Inc. Enzymatic transamination of cyclopamine analogs
EP2502078A1 (en) * 2009-11-20 2012-09-26 Infinity Pharmaceuticals, Inc. Methods and compositions for treating hedgehog-associated cancers
US9376447B2 (en) 2010-09-14 2016-06-28 Infinity Pharmaceuticals, Inc. Transfer hydrogenation of cyclopamine analogs
CN105492011A (zh) 2013-04-08 2016-04-13 丹尼斯·M·布朗 不理想给药化学化合物的治疗增效
CN104324039A (zh) * 2014-10-20 2015-02-04 付茜 一种治疗人身体表面脂肪瘤的药剂及使用方法
BR112017026103B1 (pt) 2015-06-04 2023-10-03 Sol-Gel Technologies Ltd Composições tópicas com composto inibidor de hedgehog, sistema de entrega tópica e seus usos
CN108623446A (zh) * 2017-03-24 2018-10-09 北京艾德旺科技发展有限公司 一种合成3,3-二氟环丁烷甲酸的方法

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7291626B1 (en) 1998-04-09 2007-11-06 John Hopkins University School Of Medicine Inhibitors of hedgehog signaling pathways, compositions and uses related thereto
WO2003065983A2 (en) 2002-02-01 2003-08-14 Merck & Co., Inc. 11-beta-hydroxysteroid dehydrogenase 1 inhibitors useful for the treatment of diabetes, obesity and dyslipidemia
JO2397B1 (en) * 2002-12-20 2007-06-17 ميرك شارب اند دوم كوربوريشن Terazol derivatives as beta-hydroxy steroid dihydrogenase-1 inhibitors
ATE476425T1 (de) 2003-05-29 2010-08-15 Merck Sharp & Dohme Triazolderivate als inhibitoren von 11-beta- hydroxysteroid-dehydrogenase-1
WO2005033288A2 (en) 2003-09-29 2005-04-14 The Johns Hopkins University Hedgehog pathway antagonists
JP4903133B2 (ja) 2004-04-30 2012-03-28 ジェネンテック,インコーポレイティド ヘッジホッグシグナル伝達のキノキサリン阻害剤
JP2008509146A (ja) 2004-08-06 2008-03-27 メルク エンド カムパニー インコーポレーテッド 11−ベータ−ヒドロキシステロイドデヒドロゲナーゼ−1の阻害剤としてのスルホニル化合物
ES2578728T3 (es) 2004-08-27 2016-07-29 Infinity Pharmaceuticals, Inc. Proceso para la preparación de compuestos análogos de ciclopamina
WO2006028958A2 (en) 2004-09-02 2006-03-16 Genentech, Inc. Pyridyl inhibitors of hedgehog signalling
RU2007119637A (ru) 2004-10-28 2008-12-10 Айрм Ллк (Bm) Соединения и композиции в качестве модуляторов hedgehog-пути
CA2587489C (en) 2004-11-03 2013-12-31 Curis, Inc. Mediators of hedgehog signaling pathways, compositions and uses related thereto
CN103724335A (zh) * 2005-10-20 2014-04-16 默沙东公司 用作11β-羟基类固醇脱氢酶-1抑制剂的三唑衍生物

Also Published As

Publication number Publication date
WO2008130552A1 (en) 2008-10-30
JP2010524937A (ja) 2010-07-22
US7691887B2 (en) 2010-04-06
CN101663033B (zh) 2013-01-16
JP5498936B2 (ja) 2014-05-21
EP2136803A1 (en) 2009-12-30
PE20090806A1 (es) 2009-06-27
TW200901987A (en) 2009-01-16
EP2136803B1 (en) 2012-05-02
AU2008241527B2 (en) 2014-02-13
CA2683946C (en) 2013-01-22
US20080262051A1 (en) 2008-10-23
ATE555785T1 (de) 2012-05-15
AU2008241527A1 (en) 2008-10-30
CN101663033A (zh) 2010-03-03
AR066063A1 (es) 2009-07-22
CA2683946A1 (en) 2008-10-30

Similar Documents

Publication Publication Date Title
EA201170252A1 (ru) Амидофеноксиндазолы в качестве ингибиторов c-мет
EA201171367A1 (ru) Винилиндазолильные соединения
TN2010000071A1 (en) Fused imidazoles or cancer treatment
CL2010001637A1 (es) Compuestos derivados de isoindolonas; composición farmacéutica que los comprende; y su uso como inhibidores de la quinasa mek para tratar enfermedades hiperproliferativas y/o inflamatorias tales como cáncer, artritis reumatoidea entre otras.
BR112012011086A2 (pt) uso de betanecol para o tratamento de xerostomia
EA200971068A1 (ru) Триазолиламинопиримидиновые соединения
CL2008002521A1 (es) Compuestos derivados de pirazol sustituidos, antagonista del receptor de androgeno; composicion farmaceutica que comprende a dichos compuestos; y uso del compusto para el tratamiento de cancer.
EA200970737A1 (ru) Оксабициклогептаны и оксабициклогептены, их получение и применение
CL2007002316A1 (es) Compuestos derivados de pirimidina, inhibidores de pi3k; composicion farmaceutica que comprende a dicho compuesto; y uso del compuesto en enfermedades proliferativas como cancer.
UY32882A (es) (heteroarilmetil) tiohidantoínas sustituidas
GEP20125647B (en) Kinesin inhibitors as cancer therapeutics
BRPI0914555A2 (pt) derivados de triazol bicíclicos para o tratamento de tumores
MA32900B1 (fr) Compose d'aminopyrazole
PA8843901A1 (es) INHIBIDORES DE PIRIMIDINONA DE PI3K( ALFA) Y m TOR
CL2008003200A1 (es) Compuestos derivados de tiazol, inhibidores de la proteina quinasas; composicion farmaceutica; y uso para el tratamiento del cancer, tal como cancer de vejiga, de mama y de rinon.
EA201170154A1 (ru) Производные пиридинопиридинонов, способ их получения и применение в терапии
UA107671C2 (en) N1-substityted-5-fluoro-2-oxopyrimidinone-1(2h)-carboxamide derivatives
ECSP099675A (es) Compuestos heterocíclicos, composición y métodos de uso
MX2010001093A (es) Herbicidas novedosos.
ATE555785T1 (de) Triazolderivate als smo-antagonisten
CR20120502A (es) Uso de nuevos inhibidores de pan-cdk para tratar tumores
HN2009003466A (es) Herbicidas novedosos
MA33059B1 (fr) Utilisation d'antagonistes des recepteurs nk
EA200971067A1 (ru) Триазолиламинопиримидиновые соединения
BR112018008025A2 (pt) inibidores de pdk1 heterocíclicos para uso no trata-mento de câncer